Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol
Authors:
Open Access
- 7 June 2019
- journal article
- review article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 18 (1) , 134
Abstract
Low-density lipoprotein cholesterol (LDL-C) has been recommended as the primary treatment target on lipid management in coronary heart disease (CHD) patients for past several decades. However, even by aggressive LDL-C lowering treatment, patients still present a significant residual risk of major adverse cardiovascular events (MACE). Non-high-density lipoprotein cholesterol (non-HDL-C) contained all the atherogenic lipoproteins, such as chylomicron, very-low density lipoprotein (VLDL), LDL, intermediate density lipoprotein (IDL). Many prospective observation studies have found that non-HDL-C was better than LDL-C in predicting risks of MACE. Since non-HDL-C appears to be superior for risk prediction beyond LDL-C, current guidelines have emphasize the importance of non-HDL-C for guiding cardiovascular prevention strategies and have flagged non-HDL-C as a co-primary therapeutic target. The goals of non-HDL-C were recommended as 30 mg/dl higher than the corresponding LDL-C goals, but the value seemed inappropriate. This review provide evidence for changing lipid management strategy to focus on non-HDL-C and appropriate values for adding to LDL-C goals would be proposed.Keywords
Funding Information
- National Natural Science Foundation of China (81670426, 81870336)
This publication has 76 references indexed in Scilit:
- 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the AdultCanadian Journal of Cardiology, 2013
- The effect of rosuvastatin on incident pneumonia: results from the JUPITER trialCanadian Medical Association Journal, 2012
- Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurementJournal of Clinical Lipidology, 2011
- Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk StratificationJACC, 2011
- Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22)American Heart Journal, 2011
- Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID studyBMC Medical Research Methodology, 2010
- Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best PracticesClinical Chemistry, 2009
- Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)—Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention?The American Journal of Cardiology, 2006
- Simvastatin: a reviewExpert Opinion on Pharmacotherapy, 2004
- Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the heart protection study on standards of efficacyand safetyThe American Journal of Cardiology, 2003